ERBB2 and metastatic colorectal cancer: The HERACLES‐B (NCT03225937) clinical trial was the first to explore the use of ADC in patients with RAS/BRAF wild‐type and HER2+ metastatic colorectal cancer that was resistant to chemotherapy.128